← CORCEPT THERAPEUTICS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $81.3m |
$159.2m
+95.77%
|
$251.2m
+57.82%
|
$306.5m
+21.99%
|
$353.9m
+15.46%
|
$366.0m
+3.42%
|
$401.9m
+9.80%
|
$482.4m
+20.04%
|
$675.0m
+39.94%
|
$761.4m
+12.79%
|
$830.8m
+9.12%
|
|
| Cost of Revenue | $2.1m |
$3.6m
+72.69%
|
$5.2m
+46.74%
|
$5.5m
+5.54%
|
$5.6m
+1.42%
|
$5.3m
-5.39%
|
$5.4m
+1.97%
|
$6.5m
+20.35%
|
$10.9m
+67.91%
|
$13.0m
+19.25%
|
$14.1m
+8.54%
|
|
| Gross Profit (Calculated) | $79.3m |
$155.6m
+96.37%
|
$246.0m
+58.07%
|
$301.0m
+22.33%
|
$348.3m
+15.72%
|
$360.7m
+3.56%
|
$396.5m
+9.92%
|
$475.9m
+20.03%
|
$664.2m
+39.56%
|
$748.4m
+12.69%
|
— | |
| Research and Development Expense | $23.8m | $40.4m | $75.2m | $89.0m | $114.8m | $113.9m | $131.0m | $184.4m | $246.9m | $254.9m | $253.9m | |
| Selling, General and Administrative Expense | $45.2m | $62.4m | $81.3m | $100.4m | $105.3m | $122.4m | $152.8m | $184.3m | $280.3m | $448.7m | $556.5m | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | $465k | — | — | — | |
| Operating Lease, Expense | — | — | — | $1.5m | $1.9m | $2.1m | $2.3m | $2.4m | — | — | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | $10.2m |
$52.9m
+419.26%
|
$89.5m
+69.32%
|
$111.6m
+24.71%
|
$128.2m
+14.87%
|
$124.5m
-2.91%
|
$112.6m
-9.51%
|
$107.3m
-4.75%
|
$137.0m
+27.66%
|
$44.8m
-67.29%
|
$6.4m
-85.70%
|
|
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | $116.7m | $131.6m | $126.3m | $116.9m | $125.7m | $159.6m | $62.9m | $26.4m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $125.0m | $116.2m | $124.6m | $161.5m | $66.5m | $26.4m | |
| Income Tax Expense (Benefit) | $0 | ($76.3m) | $16.7m | $22.5m | $25.6m | $12.5m | $14.8m | $18.4m | $20.3m | ($33.2m) | ($28.8m) | |
| Net Income (Loss) Attributable to Parent | $8.1m |
$129.1m
+1486.27%
|
$75.4m
-41.60%
|
$94.2m
+24.89%
|
$106.0m
+12.56%
|
$112.5m
+6.13%
|
$101.4m
-9.86%
|
$106.1m
+4.66%
|
$141.2m
+33.04%
|
$99.7m
-29.43%
|
$54.3m
-45.54%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | $8.1m |
$129.1m
+1486.27%
|
$75.4m
-41.60%
|
$94.2m
+24.89%
|
$106.0m
+12.56%
|
$112.5m
+6.13%
|
$101.3m
-9.98%
|
$105.5m
+4.15%
|
$139.7m
+32.45%
|
$98.2m
-29.74%
|
$54.3m
-44.72%
|
|
| Earnings Per Share, Basic | $0.07 | $1.14 | $0.65 | $0.82 | $0.92 | $0.97 | $0.95 | $1.02 | $1.35 | $0.95 | $0.53 | |
| Earnings Per Share, Diluted | $0.07 | $1.04 | $0.60 | $0.77 | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 | $0.45 | |
| Weighted Average Number of Shares Outstanding, Basic | 110.6m | 113.5m | 115.3m | 114.3m | 115.4m | 115.7m | 106.8m | 103.6m | 103.2m | 103.9m | 104.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | 116.1m | 124.5m | 126.7m | 122.6m | 124.2m | 126.0m | 116.0m | 111.7m | 113.5m | 120.0m | 118.1m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $71.1m | $106.3m | $161.8m | $194.9m | $225.7m | $241.5m | $289.2m | $375.1m | $538.1m | $716.6m | — | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | $23.8m | $29.4m | $33.8m | $43.2m | $42.7m | $49.1m | $61.7m | $85.0m | — |